- 1Unit of Internal Medicine and Immunology, IRCCS Ospedale San Raffaele, Milan, Italy
- 2Università Vita-Salute San Raffaele, Milan, Italy
- 3Department of Medicine, Division of Immunology and Rheumatology, Stanford University, Stanford, CA, USA
- 4Unit of Nephrology, University Hospital of Parma, Parma, Italy
The Editorial on the Research Topic
Vascular Inflammation in Systemic Autoimmunity
The immune system evolutionarily arises to integrate distant tissues and coordinate responses toward environmental or endogenous threats in complex living beings (1). To this purpose, innate and adaptive immune cells exploit the vast network provided by the vasculature, which enables information exchange and physical communication between threatened tissues and tissues in charge of immune cell generation and maturation as well as metabolism regulation (2). Clinical evidence of vascular inflammation can be easily found in settings of persisting inflammation and autoimmunity. Conversely, inflammation is a hallmark of disease progression in metabolic and cardiovascular diseases, which are the major causes of morbidity and mortality in the general population (3). If we translate these evidences into a prospect toward the future of research and clinical practice in immunology, two main questions arise:
• Can we identify shared pathogenic events among apparently unrelated human diseases that lead to vascular inflammation?
• Can we tackle these events to improve patient diagnosis, risk stratification, and treatment?
Although we are still far from satisfactorily answering these questions, here we highlight some of the emerging connections between vascular inflammation and systemic autoimmunity.
The first set of articles draws attention to some emerging players in the development and the maintenance of vascular inflammation (Figure 1). Khaib Dit Naib et al. report on the role of IL10 promoter variants in the susceptibility to Behçet’s disease, adding evidence to the postulate of a common pathogenic background between Behçet’s disease and other autoinflammatory conditions, such as Crohn’s disease (4–6), where platelet activation and smoldering vascular inflammation may occur (7, 8). Additional hints on common genetic patterns of susceptibility among diseases characterized by vessel inflammation are emerging from multicenter studies (9). Bonatti et al. and Pattanaik et al. provide a thorough and updated appraisal on this topic by analyzing two paradigmatic conditions: anti-neutrophil cytoplasmic antibodies-associated vasculitides and systemic sclerosis, the former being characterized by necrotizing vessel inflammation, the latter by chronic vessel remodeling.
Figure 1. Graphical guide to the research topic. The research topic “Vascular inflammation in systemic autoimmunity” is built on a bidirectional cross talk between clinical evidence and unsolved issues emerging from the daily rheumatology practice, at patient’s bedside, and novel discoveries coming from the bench. The Reader is, thus, invited to move from dissertations about the genetic bases of vascular inflammation toward therapeutic and diagnostic applications of most significant innovations in the field of vascular pathophysiology.
Maugeri et al. and Piotti et al. touch the pathophysiology of vascular inflammation and elegantly discuss the role of a tripartite innate immune network composed of the endothelium, platelets, and neutrophils in triggering and maintaining vessel injury as well as thromboembolic complications. In parallel, the articles by Hilhorst et al. and Lintermans et al. taken together constitute a comprehensive, cross-sectional analysis of the role of T-cells and macrophage/T-cells interactions in a wide range of inflammatory conditions, from autoimmune diseases to atherosclerosis.
The article by Piotti and colleagues and the ones by Gioffredi et al. and Pattanaik et al. demonstrate how these core mechanisms deploy in clinical settings, such as renal transplant rejection, eosinophilic granulomatosis with polyangiitis, and systemic sclerosis (Pattanaik et al.; Piotti et al.; Gioffredi et al.). Along with this line, Ammirati et al. discuss how increasing insight about the pathogenesis of vessel inflammation could be translated into clinical practice through the development of novel imaging techniques as well as novel biomarkers. The article by Luqmani moves further from bench toward bedside by reporting most updated therapeutic strategies to contrast vessel inflammation and by critically discussing current therapeutic aims and clinical tools to be considered in the treatment of systemic vasculitides, based on most recent pathogenic achievements.
In summary, we are glad to introduce the reader to this translational research topic on vascular inflammation in systemic autoimmunity, a bird’s eye view on current research trends and, in our mind, a stimulus for discussion and for future deeper investigation on the way the blood vessel and immune cells cooperate to determine vessel injury and inflammation. We really feel that this field – which had been so rewarding for scientists in the last decades – holds promises for major breakthroughs in the next future.
Author Contributions
All authors contributed in writing and revising the manuscript.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1. Loof TG, Schmidt O, Herwald H, Theopold U. Coagulation systems of invertebrates and vertebrates and their roles in innate immunity: the same side of two coins? J Innate Immun (2011) 3(1):34–40. doi: 10.1159/000321641
2. Ramirez GA, Rovere-Querini P, Sabbadini MG, Manfredi AA. Parietal and intravascular innate mechanisms of vascular inflammation. Arthritis Res Ther (2015) 17(1):16. doi:10.1186/s13075-015-0528-2
3. Libby P, Nahrendorf M, Swirski FK. Leukocytes link local and systemic inflammation in ischemic cardiovascular disease: an expanded “cardiovascular continuum”. J Am Coll Cardiol (2016) 67(9):1091–103. doi:10.1016/j.jacc.2015.12.048
4. Amre DK, Mack DR, Morgan K, Israel D, Lambrette P, Costea I, et al. Interleukin 10 (IL-10) gene variants and susceptibility for paediatric onset Crohn’s disease. Aliment Pharmacol Ther (2009) 29(9):1025–31. doi:10.1111/j.1365-2036.2009.03953.x
5. Zhou ZY, Chen SL, Shen N, Lu Y. Cytokines and Behcet’s disease. Autoimmun Rev (2012) 11(10):699–704. doi:10.1016/j.autrev.2011.12.005
6. Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behcet’s disease. Autoimmun Rev (2012) 11(10):687–98. doi:10.1016/j.autrev.2011.11.026
7. Vrij AA, Rijken J, van Wersch JW, Stockbrugger RW. Coagulation and fibrinolysis in inflammatory bowel disease and in giant cell arteritis. Pathophysiol Haemost Thromb (2003) 33(2):75–83. doi:10.1159/000073850
8. Vrij AA, Rijken J, Van Wersch JW, Stockbrugger RW. Platelet factor 4 and beta-thromboglobulin in inflammatory bowel disease and giant cell arteritis. Eur J Clin Invest (2000) 30(3):188–94. doi:10.1046/j.1365-2362.2000.00616.x
Keywords: vascular inflammation, autoimmunity, vasculitis, systemic inflammation, remodeling
Citation: Ramirez GA, Weyand C, Vaglio A and Manfredi AA (2016) Editorial: Vascular Inflammation in Systemic Autoimmunity. Front. Immunol. 7:471. doi: 10.3389/fimmu.2016.00471
Received: 02 October 2016; Accepted: 19 October 2016;
Published: 21 November 2016
Edited and Reviewed by: Pietro Ghezzi, Brighton and Sussex Medical School, UK
Copyright: © 2016 Ramirez, Weyand, Vaglio and Manfredi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Giuseppe A. Ramirez, cmFtaXJlei5naXVzZXBwZWFsdmlzZSYjeDAwMDQwO2hzci5pdA==